Jiawei Zeng
Jinghua Yan
aCAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
bUniversity of Chinese Academy of Sciences, Beijing 101408, China
More InformationCorresponding author: E-mail address: yanjh@im.ac.cn (Jinghua Yan)
Received Date: 2021-01-05
Accepted Date:2021-02-01
Rev Recd Date:2021-01-31
Available Online: 2021-03-15 Publish Date:2021-02-20
Abstract
Abstract
The ongoing COVID-19 pandemic and its unprecedented global societal and economic disruptive impact highlight the urgent need for safe and effective vaccines. Taking substantial advantages of versatility and rapid development, two mRNA vaccines against COVID-19 have completed late-stage clinical assessment at an unprecedented speed and reported positive results. In this review, we outline keynotes in mRNA vaccine development, discuss recently published data on COVID-19 mRNA vaccine candidates, focusing on those in clinical trials and analyze future potential challenges.PDF全文下载地址:
http://www.jgenetgenomics.org/article/exportPdf?id=2667c4fb-82cc-4701-90fd-371a1eba89ac&language=en
